Xenon Pharmaceuticals (XENE) news
Recent news
Xenon Pharmaceuticals 3Q oper loss $120.1M est. loss $119.3M
AInvest Wire · 7d agoXenon Pharmaceuticals 3Q loss/shr $1.11
AInvest Wire · 7d agoXenon to start Xen1701, Xen1120 phase 2 pain trials in 1H27
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) has announced plans to initiate Phase II clinical trials for two new investigational compounds, Xen1701 and Xen1120, in the first half of 2027. The trials will focus on evaluating the compounds for the treatment of chronic pain, expanding the company’s…
AInvest Wire · Oct 29, 2026Xenon reports positive phase 1 data for Xen1701 & Xen1120
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) has reported the completion of Phase 1 clinical trials for two of its novel drug candidates, XEN1701 and XEN1120, both targeting ion channels associated with pain management. The studies, conducted in healthy adult participants, were designed to evaluate…
AInvest Wire · Oct 29, 2026Starteepo sends letter to Xerox board in advance of third-quarter earnings
AInvest Wire · Oct 19, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

